文献速递冠心病血脂与心血管预防

肾功能对血小板聚集的影响:普拉格雷与氯吡格雷的比较研究

Impact of renal function on platelet aggregation: a comparative study of prasugrel and clopidogrel.
PubMed 文献 · Heart · 2026-01-27

本研究纳入164例接受双联抗血小板治疗的稳定冠心病患者,随机分配至氯吡格雷75mg或普拉格雷3.75mg每日组,按eGFR<45或≥45 mL/min/1.73 m2分层。主要终点为第5天和第30天血小板聚集抑制。结果显示在eGFR<45组,普拉格雷较氯吡格雷更快速降低血小板聚集,第5天差异显著(p=0.036),第30天不显著(p=0.105)。

要点

  • 肾功能不全患者中普拉格雷早期抑制血小板聚集更快
  • eGFR<45组第5天PRU差异显著,第30天不显著
  • 治疗效应与eGFR交互作用第5天显著(p=0.028)

核心结论

  • 在肾功能受损患者中,普拉格雷较氯吡格雷更快速降低血小板聚集,尤其在抗血小板治疗早期。
  • 需更大规模及更多样化人群研究证实。

研究设计与样本

  • 随机对照研究,纳入164例稳定冠心病接受双联抗血小板治疗患者。
  • 随机接受氯吡格雷75 mg或普拉格雷3.75 mg每日,按eGFR<45或≥45 mL/min/1.73 m2分层。
  • 主要终点为第5天和第30天血小板聚集抑制,采用协方差分析比较PRU。

主要发现

  • eGFR<45组中,氯吡格雷与普拉格雷平均PRU在基线、第5天、第30天分别为198.2 vs 177.2、214.2 vs 157.9、200.0 vs 141.7。
  • 第5天差异有统计学意义(p=0.036),第30天无统计学意义(p=0.105)。
  • 治疗效应与eGFR交互作用p值:基线0.498,第5天0.028,第30天0.212。

临床怎么用

  • 对于肾功能受损(eGFR<45 mL/min/1.73 m2)的稳定冠心病患者,若需快速抑制血小板聚集,可考虑普拉格雷。
  • 需注意本研究样本量有限,结论需进一步验证。

局限性

  • 样本量较小(164例),需更大规模研究确认。
  • 研究人群多样性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease is common in patients with coronary artery disease (CAD) and can significantly affect drug excretion and efficacy. This study focuses on the effects of modification of renal function on platelet aggregation. METHODS: In total, 164 patients with stable CAD undergoing dual antiplatelet therapy were enrolled and randomised to receive either 75 mg clopidogrel or 3.75 mg prasugrel daily. Patients were stratified based on estimated glomerular filtration rate (eGFR) into two groups: eGFR <45 (eGFR <45 group) or ≥45 mL/min/1.73 m2 (eGFR ≥45 group). The primary endpoint was the inhibition of platelet aggregation on day 5 and day 30. Analysis of covariance was performed to compare the P2Y12 reaction units (PRU) on days 5 and 30 after randomisation. RESULTS: In the eGFR <45 group, prasugrel induced a more rapid decrease in platelet aggregation than clopidogrel. Mean PRU value for clopidogrel and prasugrel at baseline, day 5 and day 30 was 198.2 vs 177.2, 214.2 vs 157.9 and 200.0 vs 141.7, respectively. The differences were statistically significant on day 5 (p=0.036), but not on day 30 (p=0.105). The p for interaction between treatment effect and eGFR was 0.498 at baseline, 0.028 at day 5 and 0.212 at day 30, emphasising that the drug effect was significantly different by kidney function, but only in the early phase of drug initiation. CONCLUSION: In patients with impaired renal function, prasugrel provided a more rapid reduction in platelet aggregation compared with clopidogrel, particularly during the early phase of antiplatelet treatment. Further research is needed to confirm these findings in larger and more diverse populations. TRIAL REGISTRATION NUMBER: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027055; Unique identifier: UMIN000023489.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Miyagi A, Maeda T, Arima H, et al. Impact of renal function on platelet aggregation: a comparative study of prasugrel and clopidogrel. Heart. 2026. PMID: 40750342. doi:10.1136/heartjnl-2024-325399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。